Armata Pharmaceuticals, Inc. Research And Development Expense

• Armata Pharmaceuticals, Inc. showed an increase of +17.3% in Research And Development Expense from 2018 to 2019.
• This data is from Armata Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2020.
• XBRL data for this metric is available from 2013 to 2019 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2013: $551.0 thousand | Q2 2013: $3.72 million | Q3 2013: $1.11 million | Q1 2014: $1.01 million | Q2 2014: $1.89 million | Q3 2014: $1.79 million | Q1 2015: $972.0 thousand | Q2 2015: $1.08 million | Q3 2015: $728.0 thousand | Q1 2016: $1.98 million | Q2 2016: $1.24 million | Q3 2016: $1.66 million | Q1 2017: $1.49 million | Q2 2017: $1.13 million | Q1 2018: $1.46 million | Q2 2018: $1.69 million | Q3 2018: $361.0 thousand | Q1 2019: $1.49 million.
• Over the full 7 years of available data (2013 to 2019), Armata Pharmaceuticals, Inc.'s Research And Development Expense has grown by 51.9%.
• Historical annual values: Fiscal year 2019: $9.82 million | Fiscal year 2018: $8.37 million | Fiscal year 2017: $2.88 million | Fiscal year 2016: $5.68 million | Fiscal year 2015: $3.99 million | Fiscal year 2014: $5.81 million | Fiscal year 2013: $6.47 million.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026